LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 121

Suchoptionen

  1. Artikel: Urgent need to address infectious diseases due to immunosuppressive therapies.

    Chastain, Daniel B / Stover, Kayla R

    Therapeutic advances in infectious disease

    2023  Band 10, Seite(n) 20499361231168512

    Sprache Englisch
    Erscheinungsdatum 2023-04-29
    Erscheinungsland England
    Dokumenttyp Editorial
    ZDB-ID 2728410-4
    ISSN 2049-937X ; 2049-9361
    ISSN (online) 2049-937X
    ISSN 2049-9361
    DOI 10.1177/20499361231168512
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.

    Chastain, Daniel B / Spradlin, Megan / Ahmad, Hiba / Henao-Martínez, Andrés F

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2024  Band 78, Heft 4, Seite(n) 811–812

    Mesh-Begriff(e) Adult ; Humans ; Glucocorticoids/adverse effects ; Opportunistic Infections/complications ; Pneumocystis ; Pneumonia, Pneumocystis/complications
    Chemische Substanzen Glucocorticoids
    Sprache Englisch
    Erscheinungsdatum 2024-04-10
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciae129
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Access to Media and Emerging Technologies: An Evolving Opportunity for Pharmacists to Contribute to Improving Health Outcomes.

    Osae, Sharmon P / Chastain, Daniel B / Young, Henry N

    Journal of pharmacy practice

    2023  Band 37, Heft 1, Seite(n) 9–10

    Mesh-Begriff(e) Humans ; Pharmacists ; Outcome Assessment, Health Care ; Internet
    Sprache Englisch
    Erscheinungsdatum 2023-01-05
    Erscheinungsland United States
    Dokumenttyp Letter
    ZDB-ID 1027474-1
    ISSN 1531-1937 ; 0897-1900
    ISSN (online) 1531-1937
    ISSN 0897-1900
    DOI 10.1177/08971900221149159
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Treatment decisions in VRE bacteraemia: a survey of infectious diseases pharmacists.

    White, Bryan P / Barber, Katie E / Chastain, Daniel B

    JAC-antimicrobial resistance

    2023  Band 5, Heft 3, Seite(n) dlad063

    Abstract: Background: VRE infections increased in 2020. High-dose daptomycin (≥10 mg/kg) has shown mortality benefit over other regimens, though daptomycin resistance is increasing. Limited data exist on the practice patterns of ID pharmacists for VRE bloodstream ...

    Abstract Background: VRE infections increased in 2020. High-dose daptomycin (≥10 mg/kg) has shown mortality benefit over other regimens, though daptomycin resistance is increasing. Limited data exist on the practice patterns of ID pharmacists for VRE bloodstream infections (VRE BSIs).
    Objectives: To describe practice patterns for VRE BSI in ID pharmacists.
    Methods: A 22-question REDCap survey was distributed to ID pharmacist members of the American College of Clinical Pharmacy (ACCP) Infectious Diseases Practice and Research Network (ID PRN) via e-mail listserv. The survey was distributed on 7 April 2022 and remained open for 4 weeks.
    Results: Sixty-eight pharmacists responded. All pharmacists completed additional training or certification in infectious diseases past their PharmD, and most (70.5%) had been practising for 10 years or less. Pharmacists at academic medical centres (80.0%) were more likely (
    Conclusions: ID pharmacists overwhelmingly selected high-dose daptomycin for VRE BSI. There were variations in practice and response rate when selecting combination therapy, managing persistent bacteraemia, and treating patients with high daptomycin MICs or previous exposure to daptomycin.
    Sprache Englisch
    Erscheinungsdatum 2023-05-22
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2632-1823
    ISSN (online) 2632-1823
    DOI 10.1093/jacamr/dlad063
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Examining the Potential of Pharmacies to Expand Pre-Exposure Prophylaxis Access Along Georgia's Fixed-Route Public Transit: A Geospatial Analysis.

    Gomez, Bryan / Roozkhosh, Farnoosh / Yao, Angela / Chastain, Daniel B / Johnson, Blake R

    Journal of the American Pharmacists Association : JAPhA

    2024  , Seite(n) 102087

    Abstract: Background: Despite accounting for more than half of new Human Immunodeficiency Virus diagnoses in the United States, the South has fewer than 30% of all pre-exposure prophylaxis users. Pre-exposure prophylaxis access geospatial analyses have focused on ...

    Abstract Background: Despite accounting for more than half of new Human Immunodeficiency Virus diagnoses in the United States, the South has fewer than 30% of all pre-exposure prophylaxis users. Pre-exposure prophylaxis access geospatial analyses have focused on drive time but analyses along public transit routes have not been evaluated. Given the proximity to pharmacists and pharmacies, involvement in pre-exposure prophylaxis services may increase access and uptake of this preventative health need.
    Objective: The objectives were to compare the rate of pre-exposure prophylaxis uptake between Georgia counties with and without public transit, to assess the geospatial accessibility of services along public transit, and to evaluate the potential impact of expanding pre-exposure prophylaxis services to community pharmacies.
    Methods: Pre-exposure prophylaxis uptake rates between counties with and without public transit were compared using the Mann-Whitney U test. Geospatial analysis was performed using ArcGIS Pro and Geoda. The Pearson correlation coefficient was used to determine the relationship between pre-exposure prophylaxis uptake rates and population and county characteristics. Spatial analysis was completed to uncover predictors for pre-exposure prophylaxis uptake rates. Increased access to pre-exposure prophylaxis along public transit was calculated by reporting the number of counties that would experience at least a 50% increase in pre-exposure prophylaxis access through community pharmacies.
    Results: Pre-exposure prophylaxis uptake is significantly higher in Georgia counties with versus without public transit (P < 0.001). Pre-exposure prophylaxis rate is positively correlated with the accessibility of community pharmacies and pre-exposure prophylaxis clinics along fixed-route public transit (R
    Conclusion: Transportation remains a barrier to accessing pre-exposure prophylaxis. Georgia community pharmacies along public transit may serve as a solution to pre-exposure prophylaxis care access barriers.
    Sprache Englisch
    Erscheinungsdatum 2024-04-05
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2118585-2
    ISSN 1544-3450 ; 1544-3191 ; 1086-5802
    ISSN (online) 1544-3450
    ISSN 1544-3191 ; 1086-5802
    DOI 10.1016/j.japh.2024.102087
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Treatment pathways, switches, and inappropriate treatment during invasive pulmonary aspergillosis: real-world experiences from a global research network study.

    Henao-Martínez, Andrés F / Chastain, Daniel B / Thompson, George R

    Antimicrobial agents and chemotherapy

    2023  Band 67, Heft 10, Seite(n) e0072123

    Abstract: Despite advancements in diagnosing and treating invasive pulmonary aspergillosis (IPA), there is limited knowledge of real-world treatment pathways and medication switches. We queried the TrinetX global research network database and identified 5,410 ... ...

    Abstract Despite advancements in diagnosing and treating invasive pulmonary aspergillosis (IPA), there is limited knowledge of real-world treatment pathways and medication switches. We queried the TrinetX global research network database and identified 5,410 patients diagnosed with IPA. The most common initial treatments were voriconazole (49%), fluconazole (11%), and posaconazole (7%). Most patients remained on voriconazole (80%) or isavuconazole (78%) throughout the treatment duration. Switches were more frequent for those initially treated with fluconazole, echinocandins, or posaconazole.
    Mesh-Begriff(e) Humans ; Voriconazole/therapeutic use ; Antifungal Agents/therapeutic use ; Invasive Pulmonary Aspergillosis/drug therapy ; Fluconazole/therapeutic use ; Echinocandins/therapeutic use ; Pulmonary Aspergillosis/drug therapy
    Chemische Substanzen Voriconazole (JFU09I87TR) ; Antifungal Agents ; Fluconazole (8VZV102JFY) ; Echinocandins
    Sprache Englisch
    Erscheinungsdatum 2023-09-06
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 217602-6
    ISSN 1098-6596 ; 0066-4804
    ISSN (online) 1098-6596
    ISSN 0066-4804
    DOI 10.1128/aac.00721-23
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults.

    Chastain, Daniel B / Spradlin, Megan / Ahmad, Hiba / Henao-Martínez, Andrés F

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2023  Band 78, Heft 4, Seite(n) e37–e56

    Abstract: Glucocorticoids are widespread anti-inflammatory medications used in medical practice. The immunosuppressive effects of systemic glucocorticoids and increased susceptibility to infections are widely appreciated. However, the dose-dependent model ... ...

    Abstract Glucocorticoids are widespread anti-inflammatory medications used in medical practice. The immunosuppressive effects of systemic glucocorticoids and increased susceptibility to infections are widely appreciated. However, the dose-dependent model frequently used may not accurately predict the risk of infection in all patients treated with long-term glucocorticoids. In this review, we examine the risks of opportunistic infections (OIs) in patients requiring glucocorticoid therapy by evaluating the influence of the glucocorticoid dose, duration, and potency, combined with biological and host clinical factors and concomitant immunosuppressive therapy. We propose strategies to prevent OIs, which involve screening, antimicrobial prophylaxis, and immunizations. While this review focuses on patients with autoimmune, inflammatory, or neoplastic diseases, the potential risks and preventative strategies are likely applicable to other populations. Clinicians should actively assess the benefit-harm ratios of systemic glucocorticoids and implement preventive efforts to decrease their associated infections complications.
    Mesh-Begriff(e) Adult ; Humans ; Glucocorticoids/adverse effects ; Opportunistic Infections/epidemiology ; Opportunistic Infections/etiology ; Immunosuppressive Agents/adverse effects ; Anti-Inflammatory Agents
    Chemische Substanzen Glucocorticoids ; Immunosuppressive Agents ; Anti-Inflammatory Agents
    Sprache Englisch
    Erscheinungsdatum 2023-09-28
    Erscheinungsland United States
    Dokumenttyp Review ; Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciad474
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Kimyrsa and Orbactiv - A Tale of Two Formulations.

    Jackson, Brittany T / Cluck, David B / Henao-Martínez, Andrés F / Chastain, Daniel B

    Drug design, development and therapy

    2023  Band 17, Seite(n) 737–742

    Abstract: Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a ... ...

    Abstract Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a similar pharmacokinetic and microbiologic profile. At present, the NF lacks significant real-world experience relative to other available lipoglycopeptides and thus its place in therapy remains difficult to predict but would not be expected to be significantly different than its OF.
    Mesh-Begriff(e) Lipoglycopeptides ; Anti-Bacterial Agents/pharmacokinetics ; Glycopeptides ; Vancomycin
    Chemische Substanzen oritavancin (PUG62FRZ2E) ; Lipoglycopeptides ; Anti-Bacterial Agents ; Glycopeptides ; Vancomycin (6Q205EH1VU)
    Sprache Englisch
    Erscheinungsdatum 2023-03-09
    Erscheinungsland New Zealand
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S324285
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel: Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis.

    Wagner, Jamie L / Jones, Bruce M / Stover, Kayla R / Cleary, John D / Bland, Christopher M / Schipper, Katie E / Chastain, Daniel B / Barber, Katie E

    Open forum infectious diseases

    2024  Band 11, Heft 5, Seite(n) ofae217

    Abstract: Daptomycin use for gram-positive infections has increased. This cost minimization analysis aimed to determine cost and/or time savings of daptomycin over vancomycin. The estimated hospital cost savings was US$166.41 per patient, and pharmacist time saved ...

    Abstract Daptomycin use for gram-positive infections has increased. This cost minimization analysis aimed to determine cost and/or time savings of daptomycin over vancomycin. The estimated hospital cost savings was US$166.41 per patient, and pharmacist time saved of almost 20 minutes per patient. Daptomycin has the potential to save both time and money.
    Sprache Englisch
    Erscheinungsdatum 2024-04-18
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofae217
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: ART-related medication errors in hospitalized people with HIV in the INSTI-era: analysis from 2 health systems in South Georgia, U.S.

    Chastain, Daniel B / Curtis, Jessica / Tang, Emily / Young, Henry N / Ladak, Amber F

    AIDS care

    2023  Band 36, Heft 6, Seite(n) 832–839

    Abstract: ... ...

    Abstract ABSTRACT
    Mesh-Begriff(e) Humans ; Medication Errors/statistics & numerical data ; Male ; HIV Infections/drug therapy ; Female ; Retrospective Studies ; Middle Aged ; Georgia ; Adult ; Anti-HIV Agents/therapeutic use ; Hospitalization
    Chemische Substanzen Anti-HIV Agents
    Sprache Englisch
    Erscheinungsdatum 2023-08-24
    Erscheinungsland England
    Dokumenttyp Journal Article ; Multicenter Study
    ZDB-ID 1012651-x
    ISSN 1360-0451 ; 0954-0121
    ISSN (online) 1360-0451
    ISSN 0954-0121
    DOI 10.1080/09540121.2023.2248564
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang